Genmab — Oktober 2020

[E_L]

SITC ID: 561
DuoBody-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13906&CONF=SITC20&ssoOverride=OFF&CKEY=

[GeorgeBest]

Thanks E L and bongobob

[E_L]

SITC ID: 412
First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13347&CONF=SITC20&ssoOverride=OFF&CKEY=

[GeorgeBest]

12:40 I like the phrase “superior”

[E_L]

Conclusions DuoBody-PD-L1×4-1BB demonstrated biologic activity and a manageable safety profile. Encouraging early clinical activity across different dose levels was observed in a heavily pretreated population with advanced solid tumors, including those resistant to prior immunotherapy or typically less sensitive to ICIs. Expansion cohorts of patients for whom DuoBody-PD-L1×4-1BB treatment could be relevant and biologically sound have started enrollment. Updated data will be presented.

[E_L]

Disease control, including stable disease at first assessment and partial responses in triple-negative breast cancer, ovarian cancer, and immune checkpoint inhibitor (ICI)–pretreated NSCLC, occurred in 40/61 patients (65.6%).

[E_L]

SITC ID: 704
Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody-CD3x5T4 in vitro and in vivo in solid cancer models https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13592&CONF=SITC20&ssoOverride=OFF&CKEY=

[Helge_LarsenPI-redaktør]

Opdaterede salgstal på Darzalex. https://www.proinvestor.com/boards/87573#87574

[E_L]

SITC ID: 617
Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13984&CONF=SITC20&ssoOverride=OFF&CKEY=

[E_L]

SITC ID: 621
A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=13536&CONF=SITC20&ssoOverride=OFF&CKEY= (camidanlumab tesirine (ADCT-301))

[Plimsoller]

Tak Helge. Projekteret i den øveste del af intervallet. Hvis det ender sådan, så kan vi ikke klage

[Bulder]

Tak bongo. Så amivantamab 100% RR i første linje (få pts ganske vist) og godkendelse om et par år.

[bongobob]

Fantastiske nyheder både Amivantamab og PD-L1x4-1BB. Duobody validated

[E_L]

TEPEZZA (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
10/14/20 https://ir.horizontherapeutics.com/news-releases/news-release-details/tepezzar-teprotumumab-trbw-data-phase-2-clinical-trial-evaluate

[E_L]

“These findings indicate this medication can provide relief at least a year after the last dose, including improvements in proptosis and diplopia, which are especially difficult symptoms to manage,”

[Solsen]

Cami still looks interesting and now in solid cancer. Wonder what Genmab will do ?

[E_L]

Yes, i am also really curious. The good thing is that Genmab can choose from strength. If they choose not to pursue it, it will not be such a big deal, as they have plenty of other stuff in their pipeline, probably more than they can handle at the moment. So we know that if they do choose to pursue it, we can be reasonably optimistic it can be successfull

[Bulder]

when was the deadline?

[E_L]

"Our collaboration and license agreement with Genmab may require a divestment of Cami, in which Genmab has a 25% interest. On June 24, 2020, we and Genmab agreed to enter into a period of good faith negotiations regarding the key financial terms of our license agreement."

[E_L]

that is all I know. I assume they are still talking